We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oncomed Pharmaceuticals and Fluidigm Corporation Announce Strategic Collaboration
News

Oncomed Pharmaceuticals and Fluidigm Corporation Announce Strategic Collaboration

Oncomed Pharmaceuticals and Fluidigm Corporation Announce Strategic Collaboration
News

Oncomed Pharmaceuticals and Fluidigm Corporation Announce Strategic Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncomed Pharmaceuticals and Fluidigm Corporation Announce Strategic Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation announced a new initiative to apply Fluidigm’s microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.

The collaboration will combine Fluidigm’s advanced microfluidic platforms with OncoMed’s proprietary cancer stem cell sorting technology to generate tools for analyzing, quantifying and developing treatments directed at a highly tumorigenic cell population.

In the initial application, OncoMed will apply Fluidigm’s BioMark™ System along with Fluidigm’s proprietary Dynamic Array™ integrated fluidic circuits (IFCs) to perform detailed gene expression analysis of solid tumors at the whole tumor and single-cell level. This phase will track changes in cancer stem cells found in human tumors following treatment with OncoMed’s extensive pipeline of therapeutic monoclonal antibodies.

The companies will apply this same technology to analyze tumor heterogeneity and cancer stem cell frequency across OncoMed’s proprietary human tumor bank which includes approximately one hundred human tumor biopsies that have been engrafted and minimally passaged in immunocompromised mice.

The OncoMed/Fluidigm collaboration also has the potential to include novel and next-generation microfluidic and tissue sample-preparation technologies that Fluidigm is currently developing.
Advertisement